Trial Profile
A pilot, case-control study of antiretroviral-naive HIV-infected patients who started a darunavir (DRV)- or rilpivirine (RPV)-based regimen to evaluate the changes in levels of circulating endothelial cells
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Apr 2017
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- 22 Mar 2017 Results published in the Journal of Antimicrobial Chemotherapy
- 02 Jan 2017 New trial record